Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | GNG2 | P59768 | 1/20 | 0.36 |
| ▸ | GNB1 | P62873 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11477205 | 0.78 | PSMB5 (0.43) | MAPKAPK2PSMB5GNG2GNB1SMAD3 | |
| SCHEMBL6615687 | 0.69 | MAPKAPK2 (0.39) | MAPKAPK2POLBPTGS1PTGS2 | |
| SCHEMBL10633407 | 0.69 | GNG2 (0.40) | MAPKAPK2PSMB5GNG2GNB1ALOX15 | |
| SCHEMBL10885614 | 0.68 | PARP1 (0.43) | PSMB5GNG2GNB1ALOX15ALOX12 | |
| SCHEMBL28588513 | 0.68 | PSMB5 (0.42) | PSMB5GNG2GNB1PTPN11POLB | |
| SCHEMBL6616962 | 0.68 | MAPKAPK2 (0.35) | MAPKAPK2ALOX15ALOX12PTGS1PTGS2 | |
| SCHEMBL10807822 | 0.67 | — | — | |
| SCHEMBL2418922 | 0.64 | MAOA (0.60) | MAPKAPK2 | |
| SCHEMBL6905745 | 0.62 | CA1 (0.36) | ALOX15 | |
| SCHEMBL6507292 | 0.62 | ALDH1A1 (0.48) | MAPKAPK2ALOX15POLBPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411063-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-10130637-B2 | Inhibition of histone methyltransferase for cardiac reprogramming | DUKE UNIVERSITY (US) | 2018-11-20 | — | — | US | disclosed |
| WO-2017134116-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-10 | — | — | WO | disclosed |
| US-20150297611-A1 | Inhibition of Histone Methyltransferase for Cardiac Reprogramming | DUKE UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| EP-2914298-A2 | INHIBITION OF HISTONE METHYLTRANSFERASE FOR CARDIAC REPROGRAMMING | Duke University (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014071323-A2 | INHIBITION OF HISTONE METHYLTRANSFERASE FOR CARDIAC REPROGRAMMING | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8003698-B2 | Site-specific inhibitors of histone methyltransferase (HMTASE) and process of preparation thereof | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2011-08-23 | — | — | US | disclosed |
| US-20110087043-A1 | Site-Specific Inhibitors of Histone Methyltransferase (HMTASE) and Process of Preparation Thereof | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH | 2011-04-14 | — | — | US | disclosed |
| EP-2303252-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC SYNDROME AND INSULIN RESISTANCE | Jungbauer, Alois (AT) | 2011-04-06 | — | — | EP | disclosed |
| US-20100292498-A1 | Site-Specific Inhibitors of Histone Methyltransferase [HMTASE] and Process of Preparation Thereof | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009137859-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC SYNDROME AND INSULIN RESISTANCE | JUNGBAUER ALOIS (AT) | 2009-11-19 | — | — | WO | disclosed |
| EP-2038247-A2 | SITE-SPECIFIC INHIBITORS OF HISTONE METHYLTRANSFERASE [HMTASE] AND PROCESS OF PREPARATION THEREOF | Jawaharlal Nehru Centre for Advanced Scientific Research (IN) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008001391-A2 | SITE-SPECIFIC INHIBITORS OF HISTONE METHYLTRANSFERASE [HMTASE] AND PROCESS OF PREPARATION THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087043-A1 | Site-Specific Inhibitors of Histone Methyltransferase (HMTASE) and Process of Preparation Thereof | EHMT1, DOT1L, CARM1 | MAPKAPK2 3150/4885PSMB5 1238/4885GNG2 3254/4885 |
| US-20100292498-A1 | Site-Specific Inhibitors of Histone Methyltransferase [HMTASE] and Process of Preparation Thereof | EHMT1, DOT1L, EHMT2 | MAPKAPK2 3124/4885PSMB5 1394/4885GNG2 2931/4885 |
| US-10130637-B2 | Inhibition of histone methyltransferase for cardiac reprogramming | EHMT2, EHMT1, DOT1L | MAPKAPK2 684/4885PSMB5 2610/4885GNG2 2865/4885 |
| US-20150297611-A1 | Inhibition of Histone Methyltransferase for Cardiac Reprogramming | EHMT2, EHMT1, DOT1L | MAPKAPK2 684/4885PSMB5 2610/4885GNG2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.